Trials / Unknown
UnknownNCT05212779
Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 45 (estimated)
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Academic / Other
- Sex
- Female
- Age
- 18 Years – 95 Years
- Healthy volunteers
- Not accepted
Summary
Blood samples and Tumor tissue will be collected at certain timepoints and will be tested.
Detailed description
Blood samples will be tested by Natera to identify residual tumor DNA for genetic changes in the tumor to potentially improve prediction of long term prognosis and guide treatment options.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Signatera testing | 26mL blood for the first blood draw and tissue sample. 20mL blood all subsequent draws. |
| DIAGNOSTIC_TEST | Altera Testing | 6ml blood and tissue sample. |
Timeline
- Start date
- 2022-10-07
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
- First posted
- 2022-01-28
- Last updated
- 2024-02-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05212779. Inclusion in this directory is not an endorsement.